• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Closing the book on Category II: time for individualized regimens for patients with recurrent tuberculosis.

作者信息

Auld Sara C, Gandhi Neel R, Shah N Sarita

机构信息

Emory University School of Medicine, Emory University Rollins School of Public Health.

Emory University Rollins School of Public Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1113-1114. doi: 10.5588/ijtld.18.0569.

DOI:10.5588/ijtld.18.0569
PMID:30236175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6385594/
Abstract
摘要

相似文献

1
Closing the book on Category II: time for individualized regimens for patients with recurrent tuberculosis.终结二类方案：是时候为复发性结核病患者制定个体化治疗方案了。
Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1113-1114. doi: 10.5588/ijtld.18.0569.
2
Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.修订后的 II 类方案可作为 I 类方案失败和不规则治疗病例再治疗的替代策略。
Am J Ther. 2011 Sep;18(5):343-9. doi: 10.1097/MJT.0b013e3181dd60ec.
3
[The effectiveness of individualized treatment regimen on smear-positive retreatment pulmonary tuberculosis with mono- and poly-drug resistance].[个体化治疗方案对涂片阳性复治单耐药和多耐药肺结核的疗效]
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Jan 12;41(1):25-31. doi: 10.3760/cma.j.issn.1001-0939.2018.01.008.
4
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.一项关于世卫组织结核病类别 II 复治方案临床结局的系统评价。
Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1127-1134. doi: 10.5588/ijtld.17.0705.
5
Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area.在艾滋病毒高流行地区，结核病复治类别可预测住院复治患者的耐药情况。
Int J Tuberc Lung Dis. 2009 Oct;13(10):1274-80.
6
Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens.耐多药结核分枝杆菌在采用标准化方案进行直接观察下的经验性再治疗期间获得耐药性。
Int J Tuberc Lung Dis. 2005 Jul;9(7):818-21.
7
Outcomes of Category II anti-tuberculosis treatment in Indian children.印度儿童二级抗结核治疗的结果
Int J Tuberc Lung Dis. 2015 Oct;19(10):1153-7. doi: 10.5588/ijtld.14.0826.
8
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.用于指导耐多药结核病再治疗方案设计的代表性药敏模式。
Int J Tuberc Lung Dis. 2006 Mar;10(3):290-6.
9
Recurrent tuberculosis: definitions and treatment regimens.
Int J Tuberc Lung Dis. 1999 Oct;3(10):851-4.
10
[The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].含异烟肼和利福平方案对单耐异烟肼或利福平肺结核的治疗效果
Zhonghua Jie He He Hu Xi Za Zhi. 2014 Dec;37(12):915-8.

本文引用的文献

1
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.一项关于世卫组织结核病类别 II 复治方案临床结局的系统评价。
Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1127-1134. doi: 10.5588/ijtld.17.0705.
2
Direct tuberculosis drug susceptibility testing: time-saving and cost-effective in detecting MDR-TB.直接结核药物敏感性检测：在检测耐多药结核病方面省时且具成本效益。
Int J Tuberc Lung Dis. 2016 Mar;20(3):323-8. doi: 10.5588/ijtld.15.0637.
3
Treatment of Tuberculosis. A Historical Perspective.结核病的治疗：历史视角
Ann Am Thorac Soc. 2015 Dec;12(12):1749-59. doi: 10.1513/AnnalsATS.201509-632PS.
4
Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience.从国家结核病规划指南中删除 II 类复治方案：格鲁吉亚的经验。
Bull World Health Organ. 2012 Jan 1;90(1):63-6. doi: 10.2471/BLT.11.092320. Epub 2011 Nov 24.
5
The answer is 17 years, what is the question: understanding time lags in translational research.答案是 17 年，问题是：理解转化研究中的时间滞后。
J R Soc Med. 2011 Dec;104(12):510-20. doi: 10.1258/jrsm.2011.110180.
6
Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.在中等收入国家引入快速、替代方法以识别耐多药结核病的成本效益分析。
Clin Infect Dis. 2008 Aug 15;47(4):487-95. doi: 10.1086/590010.
7
Cost-effectiveness of treating multidrug-resistant tuberculosis.治疗耐多药结核病的成本效益
PLoS Med. 2006 Jul;3(7):e241. doi: 10.1371/journal.pmed.0030241.
8
Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment.
Int J Tuberc Lung Dis. 2003 Jul;7(7):607-8.
9
Treatment of multidrug-resistant tuberculosis.耐多药结核病的治疗
N Engl J Med. 1993 Sep 9;329(11):784-91. doi: 10.1056/NEJM199309093291108.
10
Principles of IUATLD collaborative tuberculosis progammes.国际防痨和肺部疾病联盟合作结核病规划原则
Bull Int Union Tuberc Lung Dis. 1991 Dec;66(4):195-200.